New laboratory test accurately predicts risk of breast cancer relapse
- First test for personalized prognosis and relapse risk assessment using proteomics
- Guides post-operative adjuvant chemotherapy decision-making in early stage breast cancer, preventing over-treatment
- Achieves Level of Evidence 1 measuring uPA and PAI-1 proteins – recognized by international oncology organizations ASCO, EORTC, NACB as the most highly validated breast cancer biomarkers
- Currently in routine clinical use in Europe
Thank you for your interest in FEMTELLE. This highly accurate assay will soon be available to U.S. physicians and their breast cancer patients.
